Versant Venture Sells $7.4m in Monte Rosa Therapeutics Stock
Monte Rosa Therapeutics(GLUE.US) 10% Shareholder Sells US$7.4 Million in Common Stock
$Monte Rosa Therapeutics(GLUE.US)$ 10% Shareholder Versant Venture Capital VI, L.P. sold 1.13 million shares of common stock on Sep 20, 2024 at an average price of $6.5296 for a total value of $7.4
Monte Rosa Therapeutics(GLUE.US) 10% Shareholder Sells US$3.4 Million in Common Stock
$Monte Rosa Therapeutics(GLUE.US)$ 10% Shareholder Versant Venture Capital VI, L.P. sold 567.21K shares of common stock on Sep 11, 12, 13, 2024 at an average price of $6.0027 for a total value of $3.4
Monte Rosa Therapeutics Price Target Maintained With a $11.00/Share by Wedbush
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth
Monte Rosa Therapeutics Has Dosed The First Participants In A Phase 1, Single Ascending Dose/Multiple Ascending Dose, Healthy Volunteer Study Of MRT-6160, A VAV1-directed MGD Being Developed For Systemic And Neurological Autoimmune Diseases, Initial...
Express News | Monte Rosa Therapeutics Inc - Mrt-6160 Phase 1 Clinical Results Anticipated Q1 2025
Express News | Monte Rosa Therapeutics Announces First Participants Dosed in Mrt-6160 Phase 1 Study
Analysts Offer Insights on Healthcare Companies: Molina Healthcare (MOH), Immunovant (IMVT) and Monte Rosa Therapeutics (GLUE)
Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $17
Monte Rosa Therapeutics Analyst Ratings
Buy Rating Affirmed: Anticipated Catalysts and Undervaluation Set to Boost Monte Rosa Therapeutics
Monte Rosa Therapeutics GAAP EPS of -$0.43, Revenue of $4.7M
Express News | Monte Rosa Therapeutics Inc : JP Morgan Cuts Target Price to $7 From $9
TD Cowen Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates
Monte Rosa Therapeutics | 10-Q: Q2 2024 Earnings Report
Monte Rosa Therapeutics Expects Cash and Cash Equivalents to Be Sufficient to Fund Planned Ops and Cap Expenditures Into 1H2027
Monte Rosa Therapeutics 2Q Loss $30.3M >GLUE